Aurigene Discovery Technologies Limited-Product Pipeline Review-2015

Aurigene Discovery Technologies Limited-Product Pipeline Review-2015


  • Products Id :- GMDHC07201CDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aurigene Discovery Technologies Limited-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Aurigene Discovery Technologies Limited-Product Pipeline Review-2015', provides an overview of the Aurigene Discovery Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aurigene Discovery Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Aurigene Discovery Technologies Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Aurigene Discovery Technologies Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Aurigene Discovery Technologies Limited's pipeline products

Reasons To Buy

Evaluate Aurigene Discovery Technologies Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Aurigene Discovery Technologies Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Aurigene Discovery Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Aurigene Discovery Technologies Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aurigene Discovery Technologies Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Aurigene Discovery Technologies Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Aurigene Discovery Technologies Limited Snapshot 6

Aurigene Discovery Technologies Limited Overview 6

Key Information 6

Key Facts 6

Aurigene Discovery Technologies Limited-Research and Development Overview 7

Key Therapeutic Areas 7

Aurigene Discovery Technologies Limited-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Aurigene Discovery Technologies Limited-Pipeline Products Glance 16

Aurigene Discovery Technologies Limited-Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Aurigene Discovery Technologies Limited-Drug Profiles 19

AUR-012 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Drugs to Target Fab Pathway for Gram Negative Bacterial Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

AEA-16 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

AU-1702014 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

AU-4869 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Drugs for Cancer 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Drugs to Inhibit EZH2 for Cancer 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecule to Agonize for ROR-Gamma for Inflammation 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule to Inhibit Bruton's Tyrosine Kinase for Inflammation 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Inhibit IRAK-4 Cancer and Inflammation 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule to Inhibit PD-L1 for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AU-2439 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Drugs to Target MALT-1 for Oncology and Inflammation 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecule to Inhibit CDK7 and CDK9 for Oncology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Inhibit K-RAS for Oncology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Aurigene Discovery Technologies Limited-Pipeline Analysis 34

Aurigene Discovery Technologies Limited-Pipeline Products by Target 34

Aurigene Discovery Technologies Limited-Pipeline Products by Route of Administration 36

Aurigene Discovery Technologies Limited-Pipeline Products by Molecule Type 37

Aurigene Discovery Technologies Limited-Pipeline Products by Mechanism of Action 38

Aurigene Discovery Technologies Limited-Recent Pipeline Updates 39

Aurigene Discovery Technologies Limited-Dormant Projects 40

Aurigene Discovery Technologies Limited-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

Aurigene Discovery Technologies Limited, Key Information 6

Aurigene Discovery Technologies Limited, Key Facts 6

Aurigene Discovery Technologies Limited-Pipeline by Indication, 2015 8

Aurigene Discovery Technologies Limited-Pipeline by Stage of Development, 2015 10

Aurigene Discovery Technologies Limited-Monotherapy Products in Pipeline, 2015 11

Aurigene Discovery Technologies Limited-Partnered Products in Pipeline, 2015 12

Aurigene Discovery Technologies Limited-Partnered Products/ Combination Treatment Modalities, 2015 13

Aurigene Discovery Technologies Limited-Out-Licensed Products in Pipeline, 2015 14

Aurigene Discovery Technologies Limited-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

Aurigene Discovery Technologies Limited-IND/CTA Filed, 2015 16

Aurigene Discovery Technologies Limited-Preclinical, 2015 17

Aurigene Discovery Technologies Limited-Discovery, 2015 18

Aurigene Discovery Technologies Limited-Pipeline by Target, 2015 35

Aurigene Discovery Technologies Limited-Pipeline by Route of Administration, 2015 36

Aurigene Discovery Technologies Limited-Pipeline by Molecule Type, 2015 37

Aurigene Discovery Technologies Limited-Pipeline Products by Mechanism of Action, 2015 38

Aurigene Discovery Technologies Limited-Recent Pipeline Updates, 2015 39

Aurigene Discovery Technologies Limited-Dormant Developmental Projects,2015 40

Aurigene Discovery Technologies Limited, Other Locations 41

Aurigene Discovery Technologies Limited, Subsidiaries 41

List of Figures

Aurigene Discovery Technologies Limited-Pipeline by Top 10 Indication, 2015 8

Aurigene Discovery Technologies Limited-Pipeline by Stage of Development, 2015 10

Aurigene Discovery Technologies Limited-Monotherapy Products in Pipeline, 2015 11

Aurigene Discovery Technologies Limited-Partnered Products in Pipeline, 2015 12

Aurigene Discovery Technologies Limited-Pipeline by Top 10 Target, 2015 34

Aurigene Discovery Technologies Limited-Pipeline by Top 10 Molecule Type, 2015 37

Aurigene Discovery Technologies Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Aurigene Discovery Technologies Limited; Aurigene Discovery Technologies Limited - Key Therapeutics; Aurigene Discovery Technologies Limited - Pipeline Overview and Promising Molecules; Aurigene Discovery Technologies Limited - News; Aurigene Discovery Technologies Limited - Latest Updates; Aurigene Discovery Technologies Limited - Pipeline; Aurigene Discovery Technologies Limited - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97410
Site License
USD 3000 INR 194820
Corporate User License
USD 4500 INR 292230

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com